Skip to main content
SpringerLink
Log in

Definition, History, and Management of the Metabolic Syndrome and Management Gaps

  • Chapter
Metabolic Syndrome and Diabetes

  • 1705 Accesses

Abstract

The definition of the Metabolic Syndrome is still a work in progress despite a description of the association between visceral obesity and cardiovascular disease was already made by Morgagni back in the eighteenth century. In the absence of proper definition, the utility of the Metabolic Syndrome as tool to predict risk of future cardiovascular events or the occurrence of type 2 diabetes mellitus has inevitably been surrounded with confusion. Lifestyle modification aiming at weight loss and increased physical activity is the foundation of current management of the Metabolic Syndrome. All the components of the Metabolic Syndrome benefit from weight loss and increased physical activity. However, it is less clear to what extent the diagnosis of the Metabolic Syndrome should guide decisions involving the use of additional therapies either medical or surgical.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Enzi G, Busetto L, Inelmen EM, Coin A, Sergi G. Historical perspective: visceral obesity and related comorbidity in Joannes Baptista Morgagni’s ‘De sedibus et causis morborum per anatomen indagata’. Int J Obes Relat Metab Disord. 2003;27:534–5.

    Article  PubMed  CAS  Google Scholar 

  2. Hitzenberger K. Uber den Blutdruck bei Diabetes Mellitus. Wiener Arch Innere Med. 1921;2:461–6.

    Google Scholar 

  3. Marañon G. Uber Hypertonie and Zuckerkrankheit. Zentralblatt für Innere Medizin. 1922;43:169–76.

    Google Scholar 

  4. Kylin E. Studien über das Hypertoni-Hyperglycemi-Hyperurikemi syndrom. Zentralblatt für Innere Medizin. 1923;44:105–12.

    Google Scholar 

  5. Vague J. La differentiation sexuelle. Facteur determinant des formes de l’obésite. Presse Med. 1947;55:339–41.

    PubMed  CAS  Google Scholar 

  6. Vague J. The degree of masculine differentiation of obesities. A factor determining predisposition to diabetes, atherosclerosis, gout and uric calculous disease. Am J Clin Nutr. 1956;4:20–34.

    PubMed  CAS  Google Scholar 

  7. Kissebah AH, Vydelingum N, Murray R, et al. Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab. 1982;54:254–60.

    Article  PubMed  CAS  Google Scholar 

  8. Albrink MJ, Krauss RM, Lindgrem FT, von der Groeben J, Pan S, Wood PD. Intercorrelations among plasma high density lipoprotein, obesity and triglycerides in a normal population. Lipids. 1980;15:668–76.

    Article  PubMed  CAS  Google Scholar 

  9. Larsson B, Bengtsson C, Björntorp P, et al. Is abdominal body fat distribution a major explanation for the sex difference in the incidence of myocardial infarction? The study of men born in 1913 and the study of women, Göteborg, Sweden. Am J Epidemiol. 1992;135:266–73.

    PubMed  CAS  Google Scholar 

  10. Camus JP. Goutte, diabète, hyperlipémie: un trisyndrome métabolique. Rev Rhum. 1966;33:10–5.

    PubMed  CAS  Google Scholar 

  11. Avogaro P, Crepaldi G. Plurimetabolic syndrome. Acta Diabetol Lat. 1967;4:572–80.

    Article  Google Scholar 

  12. Haller H. Epidermiology and associated risk factors of hyperlipoproteinemia. Z Gesamte Inn Med. 1977;32:124–8.

    PubMed  CAS  Google Scholar 

  13. Hanefeld M, Leonhardt W. Das Metabolische Syndrom. Dt Gesundh Wesen. 1981;36:545–51.

    Google Scholar 

  14. Mehnert H, Kuhlmann H. Hypertonie und Diabetes Mellitus. Dtsch Med J. 1968;19:567–71.

    PubMed  CAS  Google Scholar 

  15. Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–607.

    Article  PubMed  CAS  Google Scholar 

  16. Bogardus C, Lillioja S, Mott DM, Hollenbeck C, Reaven G. Relationship between degree of obesity and in vivo insulin action in man. Am J Physiol. 1985;248:E286–91.

    PubMed  CAS  Google Scholar 

  17. Reaven GM. Syndrome X: a short history. Ochsner J. 2001;3:124–5.

    PubMed  CAS  PubMed Central  Google Scholar 

  18. Kahn SE, Prigeon RL, McCulloch DK, et al. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes. 1993;42:1663–72.

    Article  PubMed  CAS  Google Scholar 

  19. Ferrannini E, Natali A, Bell P, et al. Insulin resistance and hypersecretion in obesity. J Clin Invest. 1997;100:1166–73.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  20. Kaplan NM. The deadly quartet. Upper body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch Intern Med. 1989;149:1514.

    Article  PubMed  CAS  Google Scholar 

  21. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173–94.

    Article  PubMed  CAS  Google Scholar 

  22. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539–53.

    Article  PubMed  CAS  Google Scholar 

  23. Reaven GM. The metabolic syndrome: time to get off the merry-go-round? J Intern Med. 2011;269:127–36.

    Article  PubMed  CAS  Google Scholar 

  24. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med. 1999;16:442–3.

    Article  PubMed  CAS  Google Scholar 

  25. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–97.

    Article  Google Scholar 

  26. Bloomgarden ZT. American Association of Clinical Endocrinologists (AACE) consensus conference on the insulin resistance syndrome: 25–26 August 2002, Washington, DC. Diabetes Care. 2003;26:1297–303.

    Article  PubMed  Google Scholar 

  27. Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome--a new worldwide definition. Lancet. 2005;366:1059–62.

    Article  PubMed  Google Scholar 

  28. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–52.

    Article  PubMed  Google Scholar 

  29. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–5.

    Article  PubMed  CAS  Google Scholar 

  30. Simmons RK, Alberti KG, Gale EA, et al. The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia. 2010;53:600–5.

    Article  PubMed  CAS  Google Scholar 

  31. Povel CM, Beulens JW, van der Schouw YT, et al. Metabolic syndrome model definitions predicting type 2 diabetes and cardiovascular disease. Diabetes Care. 2013;36:362–8.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005;28:2289–304.

    Article  PubMed  Google Scholar 

  33. Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56:1113–32.

    Article  PubMed  Google Scholar 

  34. Stern MP, Williams K, González-Villalpando C, Hunt KJ, Haffner SM. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care. 2004;27:2676–81.

    Article  PubMed  Google Scholar 

  35. McNeill AM, Rosamond WD, Girman CJ, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care. 2005;28:385–90.

    Article  PubMed  Google Scholar 

  36. Woodward M, Tunstall-Pedoe H. The metabolic syndrome is not a sensible tool for predicting the risk of coronary heart disease. Eur J Cardiovasc Prev Rehabil. 2009;16:210–4.

    Article  PubMed  Google Scholar 

  37. Wannamethee SG. The metabolic syndrome and cardiovascular risk in the British Regional Heart Study. Int J Obes (Lond). 2008;32 Suppl 2:S25–9.

    Article  Google Scholar 

  38. Qiao Q, Laatikainen T, Zethelius B, et al. Comparison of definitions of metabolic syndrome in relation to the risk of developing stroke and coronary heart disease in Finnish and Swedish cohorts. Stroke. 2009;40:337–43.

    Article  PubMed  Google Scholar 

  39. Ford ES, Li C, Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care. 2008;31:1898–904.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Lorenzo C, Williams K, Hunt KJ, Haffner SM. The National Cholesterol Education Program - Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care. 2007;30:8–13.

    Article  PubMed  Google Scholar 

  41. Wilson PW, D’Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005;112:3066–72.

    Article  PubMed  CAS  Google Scholar 

  42. Noble D, Mathur R, Dent T, Meads C, Greenhalgh T. Risk models and scores for type 2 diabetes: systematic review. BMJ. 2011;343:d7163.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Vidal J. Updated review on the benefits of weight loss. Int J Obes Relat Metab Disord. 2002;26 Suppl 4:S25–8.

    Article  PubMed  Google Scholar 

  44. Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Lau J. Long-term non-pharmacological weight loss interventions for adults with prediabetes. Cochrane Database Syst Rev. 2005; (2):CD005270

    Google Scholar 

  45. Hamman RF, Wing RR, Edelstein SL, et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care. 2006;29:2102–7.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374:1677–86.

    Article  PubMed Central  Google Scholar 

  47. Orchard TJ, Temprosa M, Goldberg R, et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med. 2005;142:611–9.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  48. Siebenhofer A, Jeitler K, Berghold A, et al. Long-term effects of weight-reducing diets in hypertensive patients. Cochrane Database Syst Rev. 2011; (9):CD008274.

    Google Scholar 

  49. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr. 1992;56:320–8.

    PubMed  CAS  Google Scholar 

  50. Gregory SM, Headley SA, Wood RJ. Effects of dietary macronutrient distribution on vascular integrity in obesity and metabolic syndrome. Nutr Rev. 2011;69:509–19.

    Article  PubMed  Google Scholar 

  51. Vanhees L, Geladas N, Hansen D, et al. Importance of characteristics and modalities of physical activity and exercise in the management of cardiovascular health in individuals with cardiovascular risk factors: recommendations from the EACPR. Part II. Eur J Prev Cardiol. 2012;19:1005–33.

    Article  PubMed  CAS  Google Scholar 

  52. Cornelissen VA, Fagard RH, Coeckelberghs E, Vanhees L. Impact of resistance training on blood pressure and other cardiovascular risk factors: a meta-analysis of randomized, controlled trials. Hypertension. 2011;58:950–8.

    Article  PubMed  CAS  Google Scholar 

  53. Kelley GA, Kelley KS. Impact of progressive resistance training on lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials. Prev Med. 2009;48:9–19.

    Article  PubMed  CAS  Google Scholar 

  54. Wu T, Gao X, Chen M, van Dam RM. Long-term effectiveness of diet-plus-exercise interventions vs. diet-only interventions for weight loss: a meta-analysis. Obes Rev. 2009;10:313–23.

    Article  PubMed  CAS  Google Scholar 

  55. Eilat-Adar S, Eldar M, Goldbourt U. Association of intentional changes in body weight with coronary heart disease event rates in overweight subjects who have an additional coronary risk factor. Am J Epidemiol. 2005;161:352–8.

    Article  PubMed  Google Scholar 

  56. Simonsen MK, Hundrup YA, Obel EB, Grønbaek M, Heitmann BL. Intentional weight loss and mortality among initially healthy men and women. Nutr Rev. 2008;66:375–86.

    Article  PubMed  Google Scholar 

  57. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155–61.

    Article  PubMed  CAS  Google Scholar 

  58. Look AHEAD Research Group, Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med. 2010;170:1566–75.

    Google Scholar 

  59. Babio N, Bulló M, Salas-Salvadó J. Mediterranean diet and metabolic syndrome: the evidence. Public Health Nutr. 2009;12:1607–17.

    Article  PubMed  Google Scholar 

  60. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, Schoelles K. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292:1724–37.

    Article  PubMed  CAS  Google Scholar 

  61. Sjöström L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683–93.

    Article  PubMed  Google Scholar 

  62. Carlsson LM, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med. 2012;367:695–704.

    Article  PubMed  CAS  Google Scholar 

  63. Sjöholm K, Anveden A, Peltonen M, et al. Evaluation of current eligibility criteria for bariatric surgery: diabetes prevention and risk factor changes in the Swedish Obese Subjects (SOS) study. Diabetes Care. 2013;36:1335.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Sjöström L, Narbro K, Sjöström CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741–52.

    Article  PubMed  Google Scholar 

  65. Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007;357:753–61.

    Article  PubMed  CAS  Google Scholar 

  66. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA. 2012;307:56–65.

    Article  PubMed  Google Scholar 

  67. Ford ES, Li C, Zhao G. Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US. J Diabetes. 2010;2:180–93.

    Article  PubMed  Google Scholar 

  68. American Diabetes Association. Standards of medical care in diabetes--2013. Diabetes Care. 2013;36 Suppl 1:S11–66.

    Article  PubMed Central  Google Scholar 

  69. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–72.

    Article  PubMed  CAS  Google Scholar 

  70. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368:1096–105.

    Article  Google Scholar 

  71. DREAM On (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication Ongoing Follow-up) Investigators, Gerstein HC, Mohan V, et al. Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes. Diabetologia. 2011;54:487–95.

    Article  Google Scholar 

  72. Lamanna C, Monami M, Marchionni N, Mannucci E. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2011;13:221–8.

    Article  PubMed  CAS  Google Scholar 

  73. DREAM Trial Investigators, Dagenais GR, Gerstein HC, Holman R, et al. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care. 2008;31:1007–14.

    Article  Google Scholar 

  74. Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, Casas JP, Ebrahim S. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011; (1):CD004816.

    Google Scholar 

  75. Lee M, Saver JL, Towfighi A, Chow J, Ovbiagele B. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. Atherosclerosis. 2011;217:492–8.

    Article  PubMed  CAS  Google Scholar 

  76. NAVIGATOR Study Group, McMurray JJ, Holman RR, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362(16):1477–90.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Obesity Unit, Endocrinology and Diabetes Department, Hospital Clínic Universitari, Villarroel 170, 08036, Barcelona, Spain

    Josep Vidal M.D., Ph.D. & Amanda Jiménez M.D.

Authors
  1. Josep Vidal M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amanda Jiménez M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Josep Vidal M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Department of Surgery, NYU School of Medicine, New York, New York, USA

    Marina Kurian

  2. Department of Surgery, Oregon Health and Science University, Portland, Oregon, USA

    Bruce M. Wolfe

  3. Department of Surgery, University of Minnesota, Minneapolis, Minnesota, USA

    Sayeed Ikramuddin

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Science+Business Media New York

About this chapter

Cite this chapter

Vidal, J., Jiménez, A. (2016). Definition, History, and Management of the Metabolic Syndrome and Management Gaps. In: Kurian, M., Wolfe, B., Ikramuddin, S. (eds) Metabolic Syndrome and Diabetes. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-3220-7_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-3220-7_1

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-3219-1

  • Online ISBN: 978-1-4939-3220-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation